A first-in-human, phase I/IIa trial of the T cell immunotherapy personalised tumour trained lymphocytes in patients with advanced colorectal cancer: Study protocol
PLOS One · 2026
DOI: 10.1371/journal.pone.0351697 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift PLOS One, 2026. Verfasst von Ahmed Tarfy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of surgical sciences, UppsalaUniversity, Sweden. Hauptthemen laut MEDLINE: Colorectal Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Adoptive T cell therapy is a promising alternative to conventional therapies for certain solid tumours. Personalized tumour-trained lymphocytes (pTTL) is an autologous T cell therapy derived from tumour-draining regional lymph nodes (RLNs), trained to target patient-specific neoantigens arising from tumour-specific mutations. The protocol for an ongoing phase I/IIa first-in-human trial of pTTL in Stage IV Colorectal Cancer (CRC), NEOGAP-CRC-01, is presented here. Methods pTTL is produced by in vitro expansion of T cells from RLNs using EpiTCer® technology. Tumour-specific neoantigen-forming mutations are identified through next-generation sequencing of tumour and blood samples and the most optimal neoantigens are selected using the bioinformatics software PIOR®. Selected neoantigen epitopes are included in recombinantly produced proteins and attached to paramagnetic EpiTCer® micro-particles, forming the tumour-selective T cell stimulus TC0301 used in pTTL manufacturing. The trial comprises three parts: Part I includes sequencing of tumour and blood samples, RLNs collection, TC0301 production and pTTL manufacturing. Part II includes preconditioning, pTTL administration and 26 weeks follow-up, and Part III consists of up to five years follow-up after pTTL administration. Up to 16 patients can be included. pTTL is administered as a single-dose infusion following preconditioning with cyclophosphamide and fludarabine. Between the limits of 20 x 10 6 –1 x 10 9 cells, the entire pTTL yield will be administered. Discussion pTTL represents a novel approach within adoptive T-cell therapy, using autologous T cells trained to target selected neoantigens without genetic modification. The integration of PIOR® and EpiTCer® technology enables individualized neoantigen identification and delivery. Interpretation of treatment efficacy may be challenging due to the highly personalized nature of pTTL and the heterogeneity of CRC. The primary trial endpoint is safety. Secondary endpoints include objective treatment response, overall survival, and progression-free survival. Biomarkers of pTTL persistence, product characteristics, and treatment response will be assessed.
Trial registration
Authorized under the Clinical Trial Regulation (Regulation EU No 536/2014), EU CT #2024-512296-13-00. ClinicalTrials.gov ID NCT05908643
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of surgical sciences, UppsalaUniversity, Sweden.
- Centre for clinical research Västmanland, Uppsala University, Västerås, Sweden.
- Neogap Therapeutics AB, Stockholm, Sweden.
- Department of Clinical Neuroscience (CNS), Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Sciences, Division of Surgery, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
- Medical Unit Pelvic Cancer - Colorectal Cancer, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Ahmed Tarfy, Maziar Nikberg, Per J Nilsson, Sofia Berglund
Zitieren
APA
Tarfy, A., Salmén, A., Gafvelin, G., Grönlund, H., Chabok, A., Nikberg, M., Nilsson, P. J., Carlsten, M., Kordes, M., & Berglund, S. (2026). A first-in-human, phase I/IIa trial of the T cell immunotherapy personalised tumour trained lymphocytes in patients with advanced colorectal cancer: Study protocol. PLOS One. https://doi.org/10.1371/journal.pone.0351697
Vancouver
Tarfy A, Salmén A, Gafvelin G, Grönlund H, Chabok A, Nikberg M, et al. A first-in-human, phase I/IIa trial of the T cell immunotherapy personalised tumour trained lymphocytes in patients with advanced colorectal cancer: Study protocol. PLOS One. 2026. doi:10.1371/journal.pone.0351697
BibTeX
@article{Tarfy2026,
author = {Tarfy, Ahmed and Salmén, Andrea and Gafvelin, Guro and Grönlund, Hans and Chabok, Abbas and Nikberg, Maziar and Nilsson, Per J and Carlsten, Mattias and Kordes, Maximilian and Berglund, Sofia},
title = {A first-in-human, phase I/IIa trial of the T cell immunotherapy personalised tumour trained lymphocytes in patients with advanced colorectal cancer: Study protocol},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0351697}
}
EUVIMED